AnaptysBio expands repurchase plan after buying 3.44M shares

Rhea-AI Filing Summary

AnaptysBio, Inc. reported that its Board of Directors authorized an amendment to its Stock Repurchase Plan, allowing the company to repurchase up to an additional $100.0 million of its outstanding common stock. This expands the capital return program beyond the existing authorization.

As of November 20, 2025, $6.4 million remained available under the current $75.0 million Stock Repurchase Plan. The company has already repurchased 3,443,188 shares of common stock, representing 11.2% of shares outstanding before the start of the plan, signaling a significant reduction in its share count over time.

Positive

• Significant buyback expansion: Board authorized up to an additional $100.0 million of stock repurchases, reinforcing an ongoing capital return program.
• Notable share reduction to date: Repurchase of 3,443,188 shares, or 11.2% of pre-plan shares outstanding, meaningfully lowers the share count.

Negative

• None.

Insights

Equity Capital Markets Analyst

Large buyback expansion signals meaningful capital return and share reduction.

AnaptysBio increased its Stock Repurchase Plan by authorizing up to an additional $100.0 million of common stock repurchases. This comes on top of a prior $75.0 million authorization, of which $6.4 million remained available as of November 20, 2025. The filing notes that the plan permits repurchases of outstanding common shares.

The company has already repurchased 3,443,188 shares, equal to 11.2% of shares outstanding before the plan began. That level of activity represents a notable reduction in the share base, which can increase earnings and value per share if operating performance is stable. The incremental authorization indicates continued willingness by the Board to deploy capital toward buybacks rather than alternative uses.

Future impact on the stock will depend on the pace and pricing of any additional repurchases under the expanded authorization, as well as subsequent disclosures on execution in upcoming periodic reports or press releases.

0001370053false00013700532025-11-212025-11-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: November 21, 2025

(Date of earliest event reported)

ANAPTYSBIO, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware			001-37985			20-3828755
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

10770 Wateridge Circle, Suite 210,

San Diego, CA 92121

(Address of Principal Executive Offices, and Zip Code)

(858) 362-6295

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			ANAB			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.    Other Events.

On November 21, 2025, AnaptysBio, Inc. (“Anaptys”) issued a press release (the “Press Release”) announcing that its Board of Directors authorized an amendment to its Stock Repurchase Plan previously approved in March 2025, under which the Company may repurchase up to an additional $100.0 million of the Company’s outstanding common stock, par value $0.001 per share. This amendment is in addition to the $6.4 million that remains available under the Stock Repurchase Plan as of November 20, 2025 under the current $75.0 million Stock Repurchase Plan. Anaptys has repurchased a total of 3,443,188 shares of common stock (11.2% shares outstanding before the start of the Stock Repurchase Plan) under the Stock Repurchase Plan. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number			Exhibit Title or Description
99.1			AnaptysBio, Inc. Press Release, dated November 21, 2025.
104			Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						AnaptysBio, Inc.
Date: November 21, 2025						By:			/s/Eric Loumeau
									Name: Eric Loumeau
									Title: Chief Legal Officer

FAQ

What did AnaptysBio (ANAB) announce in this Form 8-K?

AnaptysBio announced that its Board of Directors authorized an amendment to its Stock Repurchase Plan under which the company may repurchase up to an additional $100.0 million of its outstanding common stock.

How large is AnaptysBio's existing stock repurchase authorization?

Before the amendment, AnaptysBio had a $75.0 million Stock Repurchase Plan, with $6.4 million still available for repurchases as of November 20, 2025.

How many AnaptysBio shares have been repurchased so far under the plan?

AnaptysBio has repurchased 3,443,188 shares of common stock under its Stock Repurchase Plan, which represents 11.2% of shares outstanding before the plan started.

Does AnaptysBio's amended plan specify which securities can be repurchased?

Yes. The amendment permits repurchases of AnaptysBio's outstanding common stock, par value $0.001 per share.

Where can investors find more details about AnaptysBio's repurchase announcement?

Additional details are provided in AnaptysBio's press release dated November 21, 2025, which is filed as Exhibit 99.1 to this Form 8-K.